12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Z160: Phase IIa started

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate twice-daily 375 mg Z160 for 6 weeks in up to 140 patients with chronic neuropathic pain associated with lumbosacral radiculopathy. Zalicus expects to begin a second Phase IIa trial in patients with postherpetic neuralgia (PHN) next...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >